Antisense
Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment
Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership
Sanofi Partners with Alloy Therapeutics in $400M Deal to Advance Antisense Therapeutics
Sanofi, Alloy Therapeutics, Antisense Therapeutics, Biobucks Deal, Genetic Medicine
Emerging Therapies for Huntington’s Disease: A Review of Promising Treatments
Huntington’s disease, gene therapy, antisense oligonucleotides, stem cell therapy, disease-modifying treatments
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical